{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:50:08Z","timestamp":1790437808557,"version":"4.1.0"},"reference-count":29,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T00:00:00Z","timestamp":1599264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Plasma exchange (PE) and immunoadsorption (IA) are frequently used for treatment of various autoimmune-mediated neurological diseases, including multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain\u2013Barr\u00e9 syndrome (GBS). Although both methods are generally regarded as well-tolerated treatment options, evidence for safety and tolerability is low for most indications and largely relies on small case series. In this study, we retrospectively analysed adverse events (AEs) and laboratory changes in 284 patients with various neurological indications who received either PE (n = 65, 113 cycles) or IA (n = 219, 435 cycles) between 2013 and 2020 in our Neurology department. One standard treatment cycle for PE as well as IA consisted of five treatments on five consecutive days. During every treatment, the 2.0\u20132.5-fold individual plasma volume (PV) was treated in IA, while in PE, the 0.7-fold individual PV was replaced by human albumin solution. Overall, both methods showed an excellent safety profile; no deaths of life-threatening adverse events were recorded. Severe AEs (corresponding to grade 3 on the Common Terminology Criteria for Adverse Events grading scale v5.0) including three patients with sepsis, one pneumonia, and one pneumothorax were present in 5\/435 IA cycles (1.1%); in the PE group, no severe AEs were recorded. Furthermore, although advantageous tolerability is generally considered the main advantage of IA over PE, we found that overall frequency of AEs (including grades 1 and 2) was higher in IA (67.1% of all cycles) compared to PE (35.4%; p &lt; 0.001). The low incidence of AEs in PE might be caused by the lower PV exchanged during each treatment (0.7-fold) compared to previous studies which predominantly exchanged the 1.0\u20131.5-fold PV. In order to verify this hypothesis as well as confirming the efficacy of this lower-dosed scheme, prospective studies comparing different treatment regimens are needed.<\/jats:p>","DOI":"10.3390\/jcm9092874","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T23:12:49Z","timestamp":1599433969000},"page":"2874","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6352-0909","authenticated-orcid":false,"given":"Johannes","family":"Dorst","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Fillies","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8057-161X","authenticated-orcid":false,"given":"Jens","family":"Dreyhaupt","sequence":"additional","affiliation":[{"name":"Institute for Epidemiology and Medical Biometry, University of Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2737-7495","authenticated-orcid":false,"given":"Makbule","family":"Senel","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Ulm, 89081 Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jneuroim.2008.05.026","article-title":"Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients","volume":"201\u2013202","author":"Baggi","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000332397","article-title":"Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis","volume":"33","author":"Trebst","year":"2012","journal-title":"Blood Purificat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0955-3886(94)90174-0","article-title":"Technical and clinical experience with protein A immunoadsorption columns","volume":"15","author":"Belak","year":"1994","journal-title":"Transfus. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.atherosclerosissup.2015.02.022","article-title":"Immunoadsorption with regenerating systems in neurological disorders --A single center experience","volume":"18","author":"Hohenstein","year":"2015","journal-title":"Atheroscler. Suppl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eclinm.2019.10.017","article-title":"Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial","volume":"16","author":"Dorst","year":"2019","journal-title":"EClinicalMedicine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosissup.2015.02.037","article-title":"Apheresis in treatment of acute inflammatory demyelinating disorders","volume":"18","author":"Muhlhausen","year":"2015","journal-title":"Atheroscler. Suppl."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000447059","article-title":"Escalation therapy of steroid refractory multiple sclerosis relapse with tryptophan immunoadsorption - Observational multicenter study with 147 patients","volume":"75","author":"Schimrigk","year":"2016","journal-title":"Eur. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jca.21686","article-title":"Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica","volume":"30","author":"Lipphardt","year":"2019","journal-title":"J. Clin. Apher."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lipphardt, M., Wallbach, M., and Koziolek, M.J. (2020). Plasma exchange or immunoadsorption in demyelinating diseases: A meta-analysis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051597"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1756285616637046","article-title":"Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration","volume":"9","author":"Krenzer","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.20317","article-title":"A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis","volume":"26","author":"Kohler","year":"2011","journal-title":"J. Clin. Apher."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jca.20217","article-title":"Predictors of complications in therapeutic plasma exchange","volume":"24","author":"Bramlage","year":"2009","journal-title":"J. Clin. Apher."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1744-9987.2005.00319.x","article-title":"Complications of therapeutic plasma exchange: Experience with 4857 treatments","volume":"9","author":"Kes","year":"2005","journal-title":"Ther. Apher. Dial."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000367682","article-title":"Fibrinogen reduction and bleeding complications in plasma exchange, immunoadsorption and a combination of the two","volume":"38","author":"Pablik","year":"2014","journal-title":"Blood Purif."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jca.21546","article-title":"A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy","volume":"32","author":"Lieker","year":"2017","journal-title":"J. Clin. Apher."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1744-9987.2009.00730.x","article-title":"Guillain-Barre syndrome treated by membrane plasma exchange and\/or immunoadsorption","volume":"13","author":"Svigelj","year":"2009","journal-title":"Ther. Apher. Dial."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jca.2920030313","article-title":"Nomograms for the prediction of patient\u2019s plasma volume in plasma exchange therapy from height, weight, and hematocrit","volume":"3","author":"Sprenger","year":"1987","journal-title":"J. Clin. Apher."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1007\/s00415-018-9082-6","article-title":"Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: A prospective study in 17 patients","volume":"265","author":"Dorst","year":"2018","journal-title":"J. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jnnp.72.5.596","article-title":"Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies","volume":"72","author":"Merkies","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Davies, A.J., Fehmi, J., Senel, M., Tumani, H., Dorst, J., and Rinaldi, S. (2020). Immunoadsorption and plasma exchange in seropositive and seronegative immune-mediated neuropathies. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072025"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pfeuffer, S., Rolfes, L., Bormann, E., Sauerland, C., Ruck, T., Schilling, M., Melzer, N., Brand, M., Pul, R., and Kleinschnitz, C. (2020). Comparing plasma exchange to escalated methyl prednisolone in refractory multiple sclerosis relapses. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010035"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0272-6386(12)80135-1","article-title":"Therapeutic plasma exchange: Complications and management","volume":"23","author":"Mokrzycki","year":"1994","journal-title":"Am. J. Kidney Dis."},{"key":"ref_25","first-page":"12","article-title":"Membrane plasma separation for treatment of immunologically mediated diseases","volume":"26","author":"Samtleben","year":"1980","journal-title":"Trans. Am. Soc. Artif. Intern. Organs"},{"key":"ref_26","first-page":"360","article-title":"Membrane plasma separation: Complications and monitoring","volume":"8","author":"Sprenger","year":"1984","journal-title":"Artif. Organs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1111\/j.1537-2995.2012.03663.x","article-title":"Adverse effects of plasma transfusion","volume":"52","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/bja\/aeg233","article-title":"Safety of human albumin--serious adverse events reported worldwide in 1998-2000","volume":"91","author":"Vincent","year":"2003","journal-title":"Br. J. Anaesth."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0955-3886(90)90028-H","article-title":"Therapeutic protein A immunoadsorption. A review","volume":"11","author":"Watt","year":"1990","journal-title":"Transfus. sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/9\/2874\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:07:07Z","timestamp":1760177227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/9\/2874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,5]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["jcm9092874"],"URL":"https:\/\/doi.org\/10.3390\/jcm9092874","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,5]]}}}